Cavion is a clinical-stage pharmaceutical company focused on developing innovative therapies to address neurological and rare genetic diseases. The company specializes in modulating overactive T-type calcium channels, known as Cav3, to restore natural rhythms in patients' bodies. Cavion's pipeline includes best-in-class Cav3 modulators, sourced from both internal drug discovery and in-licensing efforts. The company serves patients suffering from movement disorders and other neurological conditions, aiming to significantly improve their quality of life. Operating in the biopharmaceutical market, Cavion employs a business model centered around clinical research and development, leveraging its deep understanding of Cav3 biology and superior chemistry. Revenue is generated through the development and eventual commercialization of these therapies, as well as potential partnerships and licensing agreements.

Keywords: Cav3 modulators, neurological diseases, rare genetic diseases, clinical-stage, pharmaceutical, T-type calcium channels, movement disorders, drug discovery, patient engagement, biopharmaceutical.